Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NewLink (NLNK) Stock: Moving Average Crossover Alert
November 06, 2014
NewLink Genetics Corporation (NLNK - Snapshot Report) may be a solid choice for technical investors, as the firm saw some good news with its moving average crossover. NLNK just saw its 50 Day Moving Average break out above its 200 Day Simple Moving Average, meaning that there could be some short-term bullishness for the stock.
You could definitely argue that this has already started to take place, as shares of NLNK have jumped by 51.8% in the trailing 4 weeks. If that wasn’t enough, the company currently possesses a Zacks Rank #1 (Strong Buy), so it could have more room to run in the weeks ahead too.
More bullishness may especially be the case when investors consider what has been happening for NLNK on the earnings estimate revision front lately. No estimates has gone lower in the past two months, compared to 1 higher, while the consensus estimate has also moved higher too.
So given this move in estimates, and the positive technical factors, investors may want to watch this breakout candidate closely for more gains in the near future.
NewLink Genetics (NASDAQ: NLNK) reported Q3 EPS of ($0.20), $0.20 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $310 thousand.
http://www.streetinsider.com/Earnings/NewLink+Genetics+(NLNK)+Tops+Q3+EPS+by+20c/9982526.html
NewLink Genetics (NASDAQ: NLNK) reported Q3 EPS of ($0.20), $0.20 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $310 thousand.
Nice!!!!1 http://www.streetinsider.com/Earnings/NewLink+Genetics+(NLNK)+Tops+Q3+EPS+by+20c/9982526.html
I think 830 am tomorrow
Something strange going on, it's been dipping 4-5% but rebounding just below open every day. I feel there is some afternoon accumulation happening every afternoon
Speculation, but I expect the numbers to be in line with past performance for Q3, this will likely be more about what is on the horizon with and big cancer drug deal they just made. Who knows what else, interesting they made a point to setup a separate call about advancements
They are not getting mine!
$NLNK Sometimes you need to read between the lines before big earnings calls and advancement announcements (premarket Nov 6th). What do you think a Government contract would do to the share price here?
Nov 3, 2014
EbolaWatch: Countermeasures Compel U.S. Contracts
Drug developers specializing in Ebola treatments won’t likely need a blockbuster treatment to succeed at capitalizing on the West Africa outbreak. Ebola is likely to join anthrax and smallpox as the next infectious disease to compel the awarding of billion-dollar-plus government contracts by the U.S. alone, according to a Credit Suisse presentation.
“It is unlikely that Ebola will emerge as a viable standard commercial model for drug sales,” Credit Suisse concluded in “The Ebola Crisis,” presented Monday by research analyst Jason Kantor, Ph.D., and research associate Jeremiah Shepard, Ph.D. “The real economic ‘win’ for biotech and pharmaceutical companies will come in the form of government procurement contracts to stockpile and deploy countermeasures.”
Government agencies involved in countermeasure development and procurement “are well established and have the regulatory and financial tools to address the crisis,” the presentation found.
It cited CDC—despite public criticism of its handling of U.S. Ebola cases—as well as FDA, NIH and its National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority, the U.S. Department of Defense (DoD), the U.S. Department of Health and Human Services, and the U.S. Army Medical Research Institute of Infectious Diseases.
“We believe multiple U.S. Government procurement contracts for both vaccines and antivirals are likely to emerge as a result of the current Ebola outbreak, regardless of whether the outbreak is brought under control,” Drs. Kantor and Shepard added.
They expect Ebola to continue spreading: “Infection rate is in exponential phase in West Africa, suggesting the outbreak is likely to worsen.”
............$5M FOR rVSV-EBOV: The Welcome Trust has awarded a £3.1 million ($5 million) grant to an international consortium to fund trials of the experimental Ebola vaccine developed by Canadian and U.S. researchers. The funds will be used to rapidly assess vaccine response, and determine an optimal dose for preventive intervention, the Trust said October 29.
A total 335 healthy volunteers are to be vaccinated—20 in Germany, followed by 100 each in Gabon and Kenya, then 115 in Switzerland. The consortium will use 800 vials donated by the Canadian government to the WHO. Trials of rVSV-EBOV have already begun in the U.S., focused on dosage safety and immunogenicity comparison of single-injection and prime-boost regimens.
rVSV-EBOV uses an attenuated version of live vesicular stomatitis virus (VSV). The vaccine candidate was developed by the Public Health Agency of Canada (PHAC), and licensed by PHAC to BioProtection Systems, a subsidiary of NewLink Genetics.
http://www.genengnews.com/gen-news-highlights/ebolawatch-countermeasures-compel-u-s-contracts/81250545/
Sometimes you need to read between the lines before big earnings calls and advancement announcements. What do you think a Government contract would do to the share price here?
Nov 3, 2014
EbolaWatch: Countermeasures Compel U.S. Contracts
Drug developers specializing in Ebola treatments won’t likely need a blockbuster treatment to succeed at capitalizing on the West Africa outbreak. Ebola is likely to join anthrax and smallpox as the next infectious disease to compel the awarding of billion-dollar-plus government contracts by the U.S. alone, according to a Credit Suisse presentation.
“It is unlikely that Ebola will emerge as a viable standard commercial model for drug sales,” Credit Suisse concluded in “The Ebola Crisis,” presented Monday by research analyst Jason Kantor, Ph.D., and research associate Jeremiah Shepard, Ph.D. “The real economic ‘win’ for biotech and pharmaceutical companies will come in the form of government procurement contracts to stockpile and deploy countermeasures.”
Government agencies involved in countermeasure development and procurement “are well established and have the regulatory and financial tools to address the crisis,” the presentation found.
It cited CDC—despite public criticism of its handling of U.S. Ebola cases—as well as FDA, NIH and its National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority, the U.S. Department of Defense (DoD), the U.S. Department of Health and Human Services, and the U.S. Army Medical Research Institute of Infectious Diseases.
“We believe multiple U.S. Government procurement contracts for both vaccines and antivirals are likely to emerge as a result of the current Ebola outbreak, regardless of whether the outbreak is brought under control,” Drs. Kantor and Shepard added.
They expect Ebola to continue spreading: “Infection rate is in exponential phase in West Africa, suggesting the outbreak is likely to worsen.”
............$5M FOR rVSV-EBOV: The Welcome Trust has awarded a £3.1 million ($5 million) grant to an international consortium to fund trials of the experimental Ebola vaccine developed by Canadian and U.S. researchers. The funds will be used to rapidly assess vaccine response, and determine an optimal dose for preventive intervention, the Trust said October 29.
A total 335 healthy volunteers are to be vaccinated—20 in Germany, followed by 100 each in Gabon and Kenya, then 115 in Switzerland. The consortium will use 800 vials donated by the Canadian government to the WHO. Trials of rVSV-EBOV have already begun in the U.S., focused on dosage safety and immunogenicity comparison of single-injection and prime-boost regimens.
rVSV-EBOV uses an attenuated version of live vesicular stomatitis virus (VSV). The vaccine candidate was developed by the Public Health Agency of Canada (PHAC), and licensed by PHAC to BioProtection Systems, a subsidiary of NewLink Genetics.
http://www.genengnews.com/gen-news-highlights/ebolawatch-countermeasures-compel-u-s-contracts/81250545/
Up until now only one person has received the VSV-EBOV vaccine. In 2009, a German researcher pricked her finger with a needle she had used to inject Ebola virus into a mouse.
That lab accident sparked a transcontinental effort to figure out which of the various experimental Ebola products could be given to the woman to improve her survival chances. A group of Ebola experts settled on the Canadian vaccine.
The woman survived, but it was not clear if that was due to the vaccine, which has been shown to be useful as a post-exposure tool in primate testing. It's possible the virus never made its way into her bloodstream.
http://www.brandonsun.com/breaking-news/lab-workers-heading-home--to-winnipeg-273147281.html
Interesting, VSV-ZEBOV has been used in humans before. Once in 2009 after accidental exposure with a needle prick.
http://jid.oxfordjournals.org/content/204/suppl_3/S785.full
Keep a special eye on NLNK. On November 6th they report earnings before market open. Additionally, they have a call on the 6th to discuss recent advancements (on VSV-EBOV and their cancer treatment 1B deal)....I assume.
The last 2 days, Genentech filed for 5 new patents. They are the company that just made a deal with Newlink for 150M upfront and upto 1B for a cancer drug
http://globalipnews.com/?industry=Biotechnology&key=1W
One of the patents is for IL-17 homologous polypeptides. Google IL-17 homologous polypeptides vsv-ebov...the VSV-EBOV is Newlinks Ebola drug.
I am not doctor or pharm guy, but seems to be alot of common links. I wonder if Genentech and Newlink are going to combine forces on the Ebola situation too.
There seems to be good support here, so I don't think the bottom will fall out. There may be some folks shaking the tree to see if they can grab a couple cheap shares. I am going to hold strong, and look forward to next week's 11/6th where they announce Q3 AND advancements with their projects....which by the way only a portion is even related to Ebola.
Good find, here is a story about it.
http://amestrib.com/news/newlink-moving-toward-large-ebola-vaccine-trial
There are some things in here that will certainly be a part of the earnings call next week.
By Melissa Erickson
Associate Editor
merickson@amestrib.com
Ames-based medical vaccine research company NewLink Genetics is on the forefront of research efforts to create a vaccine that has already been shown effective in both pre- and post-exposure vaccination of primates exposed to the deadly Ebola virus.
U.S. Sen. Tom Harkin, D-Iowa, visited NewLink Thursday to hear an update on the company’s progress and to pledge his support for working to raise federal funding for biomedical research in his last months in office.
NewLink CEO Charles Link said the company has been working with the Canadian government, the U.S. government and other research companies to work “as diligently and as rapidly as possible within the bounds of safety” to prepare the Ebola vaccine for a large human trial later this year.
Right now they are working to determine the appropriate dose, Link said, and will start a 30,000 person trial in Western Africa.
If a medium-size dose of the vaccine is used, NewLink could have between 500,000 and 5 million doses available by the end of December and many more by the end of the first quarter of 2015, and if a higher dose is required, the company would have about 50,000 doses available at the end of the year, Link said.
“We think one of the medium doses is probably likely to be the effective dose, but we need data to be able to prove that, that’s what we’re trying to do right now,” he said.
“I assure you that there are literally hundreds of people moving heaven and earth trying to move these things forward, but it has to be done in a very scientifically responsible, ethically responsible way and with all the appropriate medical safety involved.”
- See more at: http://amestrib.com/news/newlink-moving-toward-large-ebola-vaccine-trial#sthash.AZrlyvkc.dpuf
I really like how everything is setting up for this beast. there is a golden cross forming which is very bullish. I think another day or two and we start seeing people lining up ready for 11/6. If we can just break those mid 40's I think we will be in great shape.
it bounced off the bottom
Hit Reuters, 5Mil Grant to test NewLink VSV-EBOV Vaccine human trials.
http://www.reuters.com/article/2014/10/29/health-ebola-vaccine-idUSL5N0SO43020141029?feedType=RSS&feedName=marketsNews
Just released....the VSV-EBOV belongs to NewLink
The Wellcome Trust announced it was funding the first human trials of a third vaccine, to start imminently, so that it can be tested in health workers and burial teams in west Africa in December, alongside two others.
The vaccine, called rVSV-EBOV, was developed by the Public Health Agency of Canada. So far it has been tested only in monkeys, but in the hope it could prove effective, 800 vials have been donated by the Canadian government. The safety trials – in which people at no risk of catching Ebola are vaccinated to ensure there are no serious side-effects – will start in Germany, Switzerland, Gabon and Kenya. The Wellcome Trust is donating £3.1m to enable the collection of safety data, overseen by the World Health Organisation.
http://www.theguardian.com/world/2014/oct/29/ebola-epidemic-turning-point-wellcome-trust
I am watching closely today, going to pick up cheap ones as I can. Next Thursday is a big day here. Promised updated to new cancer drug, and the ebola vaccine. Along with financials
The Swiss just announced that they too are testing our vaccine VSV-EOBV
http://xfinity.comcast.net/articles/news-world/20141028/EU--Ebola-Switzerland-Vaccine/
White House's Earnest Says CDC Will Later Today Offer Update, More Info on Protocols for Handling Returning Workers
Read more: http://www.benzinga.com/news/14/10/4954702/white-houses-earnest-says-cdc-will-later-today-offer-update-more-info-on-protocol#ixzz3HMv64axT
The International Union of Immunology Societies (IUIS) has called for the rapid and adequate funding of phase one and phase two human clinical trials on experimental Ebola vaccines and therapies.
http://www.laboratorytalk.com/news/union-calls-for-ebola-drug-funding/407089.article
I really wish I would have been able to grab those 34's today. Oh well, glad for the bounce.
You able to get in Wanka?
The way this dipped this morning, someone dumpped a bunch in hopes to shake the tree and load back up on some cheapies...the way in bounced back so quickly. Just my opinion.
Yep, someone is scooping them up big time!
Crap, missed the bottom my order is still sitting there.
They must have moved it up!
http://www.twst.com/update/85509-newlink-genetics-corporation-newlink-genetics-to-host-its-third-quarter-2014-earnings-results-conference-call-on-november-6-2014
Can't image people actually listen to what Cramer has to say. Anyhow, i think its a good time to load up, trying to find the bottom here, seems this may be it? Next Thursday is their earnings call where they have a special time to "discuss the results and to give an update on clinical and business development activities." I don't think they would call that out, if there wasn't something big to talk about, remembering that only a small part of this play actually has to do with the ebola hype.
NewLink Genetics Corporation will release its third quarter 2014 financial results on Thursday, November 6, 2014. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results and to give an update on clinical and business development activities.
http://www.marketwatch.com/story/newlink-genetics-to-host-its-third-quarter-2014-earnings-results-conference-call-on-november-6-2014-2014-10-27?reflink=MW_news_stmp
This is posting everywhere now.... Should make for another good week, and Monday...
http://news.nationalpost.com/2014/10/25/volunteers-jump-at-chance-to-join-experimental-ebola-vaccine-trial/
New, really good read! People are lining up to test our vaccine!
http://www.cbc.ca/news/health/ebola-vaccine-clinical-trials-in-u-s-full-of-volunteers-1.2813051
disappointing day, but good week and excellent month.
Yep! Drop was due to a PR that they didn't use any experimental vaccines on the nurse they just released from Maryland, (would have been a lot cooler if they did!), which is by the way where they are doing their testing. It's OK, chance to buy on the dip, this is a long term play, easy for me to say with an average in the mid 20's
I would like to respectfully bid the 30's adieu. We all hope to never see them again!
Hey Mike, you'll like this one even better when you see that this is much more than and ebola play, actually that is just a fraction of it. Check the 8K from this week....
http://ih.advfn.com/p.php?pid=nmona&article=64098058